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Summary This study aimed to estimate the prevalence and type of chronic gastritis is an asymptomatic
working population and to determine whether a combination of serum pepsinogen levels and Helicobacter
pylori serology could be used to identify a subgroup with atrophic gastritis at elevated risk of gastric
carcinoma. A 10% subsample of 544 male volunteer factory workers aged 18-63 years and participating in a
larger study underwent endoscopy and biopsy. Of these men, 29 were seropositive for Helicobacter pylori; all
but three (89.7%) had chronic gastritis. Serum pepsinogen A levels increased with progression from a corpus
predominant pattern of gastritis through pangastritis to an antral predominant pattern. Nine subjects had
corpus atrophy, which was in most cases accompanied by fasting hypochlorhydria and hypergastrinaemia. A
combination of pepsinogen A below 80 ng ml-' and Helicobacter pylori seropositivity detected corpus atrophy
with sensitivity 88.9% and specificity 92.3%. A second screening stage, using a pepsinogen A/C ratio of below
2.5 as a cut-off, resulted in a reduction in numbers requiring further investigation but with some loss of
sensitivity (77.8%). Application of this two-stage screening programme to the original sample of 544 workers
would have resulted in 11 (2.2%) men being selected for follow-up, excluding 25 (5.1%) false negatives. Our
results suggest that a combination of serum pepsinogen levels and Helicobacter pylori serology could be useful
as a biomarker strategy for detection of individuals at increased risk of gastric carcinoma and for non-invasive
investigation of the natural history of Helicobacter pylori gastritis.
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Helicobacter pylori infection, associated with chronic gastritis,
is known to be very common among the general population
(Dixon, 1992; Webb et al., 1994). The development ofchronic
gastritis is thought to be a vital first stage in gastric
carcinogenesis (Correa, 1988), leading to the development
of atrophy, which increases the risk of gastric carcinoma. It
has been estimated that 10% of patients with chronic
atrophic gastritis (CAG) develop gastric cancer in 10- 15
years (Jass, 1980) and those with corpus atrophy have a 4- to
5-fold increased risk (Varis et al., 1983; Sipponen et al.,
1985). H. pylori chronic gastritis is also strongly associated
with peptic ulcer (Dixon, 1992; Sipponen, 1991). The
majority of those infected with H. pylori will have,
however, uncomplicated and asymptomatic chronic gastritis.
The development of peptic ulcer or adenocarcinoma against a
background of H. pylori gastritis depends, at least in part, on
the pattern of chronic gastritis (e.g. corpus or antrum
predominant or pangastritis) and the presence or absence of
glandular atrophy (Price, 1991; Dixon, 1994; Wyatt, 1995).
Pepsinogen is secreted as two biochemically distinct groups
of isozymes: pepsinogen A (PGA) and C (PGC). Both are
secreted by the chief and mucous neck cells of the gastric
fundus and corpus and PGC is also secreted by the pyloric
glands in the antrum and Brunner's glands in the proximal
duodenum (Samloff, 1989). Initially, in mild inflammation,
circulating levels of both pepsinogens are increased and
elevated PGA levels have been associated with peptic ulcer
disease (Samloff, 1989). The development of corpus atrophy,
however, is associated with a decrease in PGA levels. Chief
cells are gradually replaced by pyloric glands as the severity
of disease increases, the result being a decrease in PGA but
maintenance of (or increased) PGC levels. As a consequence,
the ratio of PGA to PGC (A/C) in serum decreases (Varis et
al., 1979, 1991; Miki et al., 1987; Westerveld et al 1987;
Kekki et al., 1991; Sitas et al., 1993).
Many of the original data relating pepsinogen levels to
pathology (referred to above) were derived from studies of
patient groups and relatives of pernicious anaemia suffers.
Many endoscopically 'normal' subjects used as controls in
these previous studies may have had H. pylori gastritis rather
than normal mucosa. The 'normal range' arising from such
work may therefore need to be redefined in subjects of known
H. pylori status.
In this study, known locally as the 'Stoke Stomach
Project', we aimed to estimate the prevalence and type of
chronic gastritis in normal healthy males in the UK and
study the interrelationships between H. pylori infection,
serum PG and gastrin levels, and gastric pathology, to
determine whether any combination of these could be used as
markers for histologically defined chronic gastritis with
atrophy. Those involved in 'dusty' industries, such as steel
and cement workers, miners and workers in the pottery and
rubber tyre industries, have all been reported to show higher
than expected rates of gastric cancer (Brandt-Rauf, 1987;
Sorahan et al., 1989; Coggon et al., 1990). The volunteers
were therefore recruited from workers in these types of
industries in Stoke-on-Trent, previously shown to be
associated with an increased risk of gastric carcinoma
(Veys, 1985). The study population was, therefore, one in
which the likelihood of detecting the pathology of interest
would be raised, although dust levels would have been
significantly reduced over recent decades.
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Methods
Random non-fasting blood samples for measurement of
serum PG and anti-H. pylori IgG levels were obtained from
male volunteers (who were employees at four factories in
Stoke on Trent within the ceramics, steel and rubber tyre
industries) recruited during 'health and fitness' checks or
blood donor sessions. The blood samples for PG were
allowed to clot at room temperature before being centrifuged
to separate out the serum. Sera were kept at 4°C until
transfer to a -70°C facility at the end of the day (8 h
maximum).
Serum PGA and -C levels were measured by radio-
immunoassay, either by a commercially available kit (PGA
Sorin Biomedical) or an in-house assay (PGC) (Hengels and
Strohmeyer, 1989).
Anti-H. pylori IgG levels were measured in serum
samples using an established ELISA (Steer et al., 1989)
which was slightly modified (Talley et al., 1991) and
subjects were classified as H. pylori seropositive or
seronegative using a cut-off of greater than
10 jug IgG ml-' to indicate positivity. The method has
previously been shown to give a sensitivity of 96% and a
specificity of 93% (Talley et al., 1991).
Based on previous published data (referred to above), we
defined abnormal serum PGA levels as below 25 ng ml-1 and
above 150 ng ml-'. Subjects with abnormal PGA levels were
age-matched on a group basis with subjects with PGA levels
ranging from 25 to 150 ng ml-'. None of these men were
concurrently undergoing treatment of gastric problems. The
men were asked to undergo endoscopy and biopsy, with two
samples each from antrum, angulus and corpus. Gastric juice
samples for pH measurement were aspirated at the beginning
of endoscopy and 10 ml of blood was collected into
heparinised tubes for gastrin analysis by routine assay
(Regional Regulatory Peptide Laboratory, Royal Victoria
Hospital, Belfast) using the methods of Ardill (1979). Inter-
and intra-assay variation for the assay series was 9.4% and
6.6% respectively.
Histology
Gastric biopsies were routinely processed and sections stained
with haematoxylin and eosin for typing and grading of
gastritis, Giemsa for detection of H. pylori and AB/PAS for
detection of intestinal metaplasia. The Sydney System (Price,
1991) was used to categorise the pattern of gastritis present
and its severity. Briefly, the Sydney System recognises acute,
chronic and special forms ofgastritis; most chronic gastritis is
H. pylori associated and the degree of neutrophil and
mononuclear cell infiltration, atrophy, intestinal metaplasia
and H. pylori colonisation are separately graded 0-3. Special
forms of gastritis have distinctive histological features and
include lymphocytic gastritis and reactive gastritis.
The study was approved by the local Medical Research
Ethical Committee. The epidemiological aspects of this study
will be published in detail elsewhere (Knight et al., 1995).
Results
Study sample
A total of 544 men were initially recruited into the study,
aged 18-63 years (median 43 years).
Serum pepsinogen levels and serodiagnosis of H. pylori in the
study sample
Data on PGA levels were available for all 544 men and data
on H. pylori serology were available for 497 men. Figure 1
describes the distribution of PGA levels in H. pylori
seronegative and seropositive subjects, showing a unimodal
pattern with an additional peak at levels over 150 ng ml-' for
the seropositive subjects. The cut-off levels chosen were
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Figure 1 Distribution of PGA levels in H. pylori seronegative
and seropositive subjects. _, Seropositive; m, seronegative.
Selection ofsubgroup
Of the 544 men in the study sample, nine (1.7%) had a PGA
<25 ngml-' and 19 (3.5%) a PGA >150ngml-'. These
were age matched (±5 years) with 48 men with PGA levels
between these two values (the so-called 'normal' range). This
subgroup was asked to undergo endoscopy and biopsy for
histological diagnosis. Of the 76 men selected, 56 agreed
(73.7%) and 54 were eventually successfully endoscoped,
representing a 10% subsample ofthe original study sample of
544 men: six ofnine with PGA levels below 25 ng ml-', 14 of
19 with PGA over 150 ng ml-' and 34 of 48 with 'normal'
values.
Endoscoped subgroup: relationships between histology, serology
and biomarkers
Positive titres ofH. pylori IgG antibodies (>10jIg IgG ml-l)
were found in 29 of the 54 endoscoped subjects; five of six
subjects with serum PGA <25 ng ml-', 12 of 14 subjects
with PGA > 150 ng ml-' (85.7%) and 12 of 34 of those with
PGA levels between 25 and 150 ng ml-' (35.3%). Twenty-six
of the 29 seropositive subjects had histological gastritis, of
which H. pylori were detected histologically in 20 (76.9%). Of
the remaining six, five had lymphocytic gastritis (all with
strongly positive titres) and one with a weak response had
gastritis with dense Gastrospirillum hominis colonisation.
Three seropositive subjects (10.3%) and all 25 who were
seronegative had histologically normal mucosa at all sites.
Group 1: subjects with serum PGA < 25 ng ml-' Five ofthe
six seropositive subjects had histological gastritis, which was
mainly corpus predominant with corpus atrophy (Figure 2)
and accompanied by high gastric juice pH (>7 in four of
five) (Figure 3), a high serum gastrin (>400 ng l- in four of
five) (Figure 4) and low PGA/C ratio (<2.0) in five of five
(Figure 5). Three subjects had lymphocytic gastritis affecting
their corpus mucosa. The only two endoscoped subjects with
intestinal metaplasia in corpus mucosa were also in this
group. The one seronegative subject had normal histology
and normal gastric pH (1.9), serum gastrin (40 ng 1-') and
PGA/C (7.5). The combination of low serum PGA, low
PGA/C ratio and H. pylori seropositivity therefore identified
subjects with the histological and pathophysiological char-
acteristics of atrophic gastritis involving corpus mucosa.
Group 2: subjects with serum PGA 25-150 ng ml-' Of the
12 seropositive subjects in this group, nine (75.0%) were also
histologically positive for H. pylori and had chronic gastritis
(Figure 2). Two of these nine subjects had corpus
predominant gastritis and corpus atrophy, PGA levels of
48.4 and 50.3 ng ml-' PGA/C level <2.5, gastrin levels
> 100 ng 1' and gastric pH >4.0. These thus resembled the
H. pylori seropositive subjects with low PGA (<25 ng ml-').
Two other subjects had pangastritis with corpus atrophy;
their PGA levels were 61.4 and 75.6 ng ml-'. Further dataSerology Histology
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Hp-(1) Normal (1) Absent
Group 1
PGA <25 ng mF1 Corpus predominant (4) Present (3)
n=6 \___/__\
Hp + (5) Chronic gastritis (5) Inadequate biopsy (1)
Pangastritis (1) Present (1)
Group 2 Hp - (22) Normal (25)
PGA 25-150 ng mlF1 (3)
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Antrum predominant (1) Absent(1)
Group 3 Hp- (2) Normal Absent
PGA >150 ng ml1< Present (1)
n= 14 Hp + (12) Chronic gastritis (12) Pangastritis (4) Absent (3)
Antrum predominant (5) Absent (5)
Antrum only (3)t Absent (3)
Figure 2 Histological diagnosis in 54 endoscoped subjects. *Subjects also with lymphocytic gastritis. tSubject with Gastrospirillum
gastritis.
were available for one of these only and he had A/C >2.5,
gastrin <100 ng I' and pH <4.0. Another subject with
pangastritis had antral atrophy; his PGA level was
67.4 ng ml-', PGA/C >2.5, gastrin >100 ng ml-' (pH data
10
not available). The remaining four of the nine subjects had
chronic gastritis but no atrophy. These had PGA levels
>90 ng ml'-, PGA/C >2.5, gastrin <100 ng I` and gastric
pH <4.0. The PGA-lowering effect of corpus atrophy
appeared therefore to be moderated by the distribution of
the associated gastritis.
Two of the three H. pylori seropositive subjects with
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Figure 4 Gastrin levels within PGA groups. El, Gastritis; C,
normal.
Figure 5 (a) Pepsinogen C levels within PGA groups, (b)
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>2.5, gastrin <100 ng I`, gastric pH <4.0). The third had
oesophageal ulcer noted on endoscopy; he had PGA
<50 ng ml-' and gastric pH >4.0.
All 22 H. pylori seronegative subjects had normal
histology and 'normal' biochemical profiles (PGA/C >2.5,
gastrin <100 ng `', gastric pH <4.0).
Group 3: subjects with serum PGA > 150 ng ml-' Twelve of
the 14 subjects in this group were seropositive for H. pylori
(85.7%) and had gastritis. The pattern of gastritis in this
group was entirely different from that in Group 1 and 2
subjects, being mainly antrum predominant; only one had
mild corpus atrophy. Intestinal metaplasia was present in the
antrum and/or angulus biopsies only, of four subjects. One
patient had Gastrospirillum hominis-associated gastritis
affecting the antrum only (Figure 2) and a PGA level of
227 ng ml-'. Serum gastrin and PGC levels were measured in
10 of the 12 H. pylori seropositive subjects. Their mean serum
gastrin level was 92.5 ng 1-l (s.d. 28.1 ng 1-') and mean
PGA/C ratio 8.2 (s.d. 2.5). None had a PGA/C ratio <4.0.
Two of eight had fasting pH >2.5, not accompanied by
either raised serum gastrin, or low PGA/C ratios, and
therefore unlikely to represent sustained hypochlorhydria
(gastric pH>4.0). Thus the biochemical indices in this group
are consistent with absence of corpus atrophy. The two
subjects who were seronegative for H. pylori were
histologically normal, with normal gastrin (60 ng 1-1),
PGA/C (>5.0) and low gastric pH (<2.0).
Precision of PGA and H. pylori serology for prediction of
corpus atrophy
A series of calculations of sensitivity and specificity were
undertaken on the subgroup results for various levels of
serum PGA alone or in combination with H. pylori
seropositivity. A combination of PGA <80 ng ml-l and H.
pylori seropositivity provided the best option in terms ofboth
sensitivity and specificity. This combination of biomarkers
predicts the presence of corpus atrophy with sensitivity
88.9% and specificity 92.3% (Table I). Using these criteria,
one of nine subjects with corpus atrophy was falsely classified
as negative (11.1%). This subject had PGA levels
> 150 ng ml-' but only had mild (grade 1) corpus atrophy.
Three of 39 subjects without corpus atrophy were falsely
classified as positive (7.7%) and, although they did not have
corpus atrophy, two of them did in fact have some upper
gastrointestinal tract pathology: antral atrophy and oesopha-
geal ulcer. Only one had a completely normal mucosa.
Application of the chosen 'screening' criteria to the original
study sample
In our study sample, data on both serum PGA and H. pylori
serology were available for 497 men. Of these, 96 (19.3%)
were both seropositive for H. pylori and had PGA
<80 ng ml-' and so would have been selected as having
corpus atrophy by the screening test. Of these 96, 27.3%
would be expected to be false positives (n =26). Further
extrapolation from our subsample suggests that about a third
of the 26 false positives (n=9) would have a normal mucosa
and the rest (n = 17) would have some other upper
gastrointestinal tract pathology (although no corpus atro-
phy). In 75% of the 96 men selected, corpus atrophy may
have been accompanied by hypochlorhydria and hypergas-
Table I 2 x 2 contingency table for prediction of corpus atrophy by
serological tests: PGA, <80 ng ml-- and H. pylori seropositivity
Histology
Serology Corpus atrophy No corpus atrophy
Corpus atrophy 8 3
No corpus atrophy 1 36
trinaemia. Of the 401 men who would have been cleared as
not having corpus atrophy, 2.7% (n=11) would have been
wrongly excluded from the follow-up group and in fact
would be expected to have corpus atrophy.
Second screening stage
Previous studies have indicated that use of the PGA/C ratio
significantly improves the validity of serum pepsinogen as a
screening test (Miki et al., 1987, 1993; Westerveld et al., 1987;
Samloff, 1989). Based on these data we added a second
screening stage of PGA/C ratio <2.5 to the subgroup. This
resulted in detection of corpus atrophy with maximum
specificity (100%) but lower sensitivity (77.8%) (Table II)
due to the loss of one subject with corpus atrophy, falsely
classified as negative. This subject however, had only mild
(grade 1) atrophy without hypochlorhydria or hypergastri-
naemia. It is likely that ifthe severity ofhis disease increased,
a repeat screen, say, 5 years later, would detect his atrophy
due to reduced PGA and A/C ratio. Application of this
second stage to our selected group of 96 men would have
resulted in 11 (2.2% of the original sample of 497 men)
remaining in a group requiring invasive investigation. In
total, 14 of the 85 men excluded at this stage would have
been false negatives for corpus atrophy. Thus, in total, over
the two stages 25 (5.1% of 486) would have been wrongly
excluded, although as discussed above, it is likely that these
would have been detected at a later screening if the severity
of their disease had increased. The assay cost per case of
corpus atrophy detected would have been approximately
£500. On the basis of our data using a two-stage screening
programme in males employed in an industrial setting in
Stoke-on-Trent (an area with rates of gastric cancer over
30% higher than the national average), 2.2% (22 per 1000) of
those screened would require further investigation (by
endoscopy and biopsy). This figure is of the same order as
screen detected lesions in mammography (50-60 per 1000).
Discussion
The results ofthis study indicate that use ofPGA levels alone
is not a reliable enough indicator of the presence of gastritis
and corpus atrophy in a non-patient population; of the six
men with very low PGA levels (<25 ng ml-'), one had
normal mucosa and of 14 men with very high levels
(> 150 ng ml-1), two (14.3%) had normal mucosa. Of those
with 'normal' PGA levels between these two extremes, nine
men (26.5%) had chronic gastritis, some with antral or
corpus atrophy. Combining PGA levels with H. pylori
serology greatly increased the precision with which those
with significant upper gastrointestinal pathology were
detected. The addition of PGC levels for the calculation of
PGA/C ratio, would reduce the number of subjects referred
for invasive and expensive investigation but with reduced
sensitivity in terms of cases of corpus atrophy detected. Those
selected, however, would be more likely to have corpus
atrophy accompanied by hypochlorhydria, the 'classic'
scenario for increased risk of gastric carcinoma.
There was clearly an association between the pattern of
gastritis and PGA levels, with the proportion of corpus
predominant gastritis decreasing and of pangastritis and
antral predominant gastritis increasing with increasing PGA
levels. This non-invasive technique appears, therefore, to
Table II 2 x 2 contingency table for prediction of corpus atrophy
by serological tests: PGA<80 ng ml- , PGA/C<2.5 and H. pylori
seropositivity
Histology
Serology Corpus atrophy No corpus atrophy
Corpus atrophy 7 0
No corpus atrophy 2 39Population in for gastuic alrophy
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provide valuable information about the overall spectrum of
gastritis in H. pylori seropositive people and would allow
different patterns of gastritis to be studied in different
population groups. In addition, factors affecting the
progression of gastritis to antrum or corpus predominant
patterns could be investigated.
Ulcers were seen at endoscopy in only 2 of the 54 subjects
endoscoped. One with a duodenal ulcer had antrum
predominant H. pylori gastritis on histology and was
seropositive with a PGA of 114.4 ng ml-'. The second had
an oesophageal ulcer, was weakly seropositive for H. pylori
but histologically had normal gastric mucosa. He was also
hypochlorhydric (pH 6.2) but did not have raised serum
gastnn.
H pylori-associated gastritis is therefore a heterogenous
condition histologically. Some individuals have an antrum
predominant pattern of disease; these may develop duodenal
ulceration but have a reduced risk of developing gastric
cancer (Lee et al., 1990). Others have pangastritis or corpus
predominant gastritis with progressive mucosal atrophy and
are at increased risk of developing gastric carcinoma. The
precise factors that determine the topographical pattern or
progression of the gastritis are not currently known.
The 26 cases of gastritis in the endoscoped group included
20 associated with H. pylon and six of 'special forms' of
gastritis; five of lymphocytic gastritis and one of Gastro-
spirillwn hominis infection. Surprisingly, no examples of
reactive gastritis were detected, in contrast to a frequency
of about 10% of endoscopic gastric biopsies from routinely
endoscoped symptomatic patients seen by the same pathol-
ogist. This suggests that reactive gastritis is uncommon in the
healthy population and thus may be symptomatic in a high
proportion of cases. Lymphocytic gastritis is a distinctive
condition histologically, which, in our experience, is typically
H. pylon negative on histology but positive on serology. It is
seen in up to 4% of biopsies from endoscoped patients with
gastritis (Dixon et al., 1988) and so the finding ofthis pattern
in 5/26 (19.2%) patients with gastritis in this study is
surprisingly high. However, three of these five were among
the Group 1 patients with low PGA and corpus atrophy,
which explains their selection for endoscopy. Surprisingly,
subjects with lymphocytic gastritis tended to be younger
(median age 34, four of five aged <40 years) than other
seropositive subjects with gastritis (median age 48, 5/20 aged
<40 years). Three of four with adequately deep corpus
biopsies showed a degree of atrophy, supported by
hypochlorhydria and high serum gastrin, suggesting that
lymphocytic gastritis may have a high frequency of
progression to corpus atrophy at a relatively young age.
Atrophic corpus mucosa and hypochlorhydria are well
known to be associated with increased risk of gastric
carcinoma. Griffiths et al. (1994) recently found a frequency
of lymphocytic gastritis of 12% in non-neoplastic mucosa in
patients who had gastric adenocarcinoma and in those with
B-cell lymphoma. Clearly, the significance of lymphocytic
gastritis as a possible premalignant condition warrants
further study. Weak serological cross-reactions with H.
pylon antigens have previously been recognised in patients
with Gastrospirillun hominis infection, which is estimated to
account for about 0.2% cases of chronic gastritis (Heilmann
and Borchard, 1991).
conclusion
Pepsinogen A and C levels and A/C ratio are non-invasive
markers for gastritis of value in both epidemiological and
clinical studies. Our results indicate that their use in
combination with H. pylori serology could form the basis
of a biomarker strategy likely to prove useful in high-risk
population groups, such as first-degree relatives of gastric
cancer cases (Graham and Lilienfield, 1958; Langman, 1988)
or those in occupational groups traditionally associated with
an increased risk ofgastric cancer. Gastric carcinoma is more
common in men than women. The study was conducted
amongst a male population and therefore the results may not
be applicable to a female population. The results ofthis work
build upon, and are consistent with, data from studies
conducted within different populations around the world.
Further research is now needed to test the validity of the
proposed test in women and to evaluate the proposed
screening programme in terms of feasibility and effectiveness
in target populations.
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